Released: 27/04/2020 – 14:19 GMT
RNS Number: 0073L
Kedrion S.p.A.
Castelvecchio Pascoli (Lucca, Italy), 27 April 2020 – The Annual General Meeting of Shareholders of Kedrion S.p.A. has approved today the individual financial statements of the Company for the year ended 31 December 2019 and has acknowledged its 2019 consolidated financial statements.
READ THE CONSOLIDATED FINANCIAL STATEMENTS 2019
About Kedrion Biopharma
Kedrion Biopharma is a leading international biopharmaceutical company that specializes in the development, production and distribution of plasma-derived therapeutic products for use in treating serious diseases, disorders and conditions such as immune system deficiencies and coagulation disorders. Kedrion has special expertise in the treatment of rare diseases and in the manufacture of hyper-immune products such as anti-hepatitis B, anti-tetanus and RhoGAM for prophylaxis against Rh sensitization and subsequent hemolytic disease of the fetus and newborn. The company operates through a fully integrated business model from the collection of plasma in its own centers in the United States and Hungary to fractionation and production in its manufacturing facilities located in Italy, Hungary and the United States. Headquartered in Castelvecchio Pascoli (Italy), Kedrion has over 2,500 employees and a commercial presence in approximately 100 countries worldwide. Kedrion places a high value on the welfare of those who benefit from its products, as well as on the people and the communities it serves. Additional information about Kedrion Biopharma can be found at www.kedrion.com and www.kedrion.us.
